MacroGenics Announces Sale of TZIELD™ Royalty Interest for
ROCKVILLE, MD, March 08, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and...
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2023-03-09, 05:48
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2023-03-08, 06:01
MacroGenics Announces Date of Fourth Quarter 2022 Financial
ROCKVILLE, MD, March 07, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and...
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2023-02-07, 04:59
MacroGenics to Participate in Upcoming Investor
ROCKVILLE, MD, Feb. 06, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing...
